Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia

Experimental Hematology

Volumn 38, Issue 12, 2010, Pages 1167-1177

  Danilov, Alexey V ^a   Danilova, Olga V ^b   Brown, Jennifer R ^c   Rabinowitz, Arthur ^d   Klein, Andreas K ^a   Huber, Brigitte T ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AX 8819; B LYMPHOCYTE RECEPTOR; DIPEPTIDYL PEPTIDASE II; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN; PEPTIDE HYDROLASE; PEPTIDE HYDROLASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE ZAP 70; PROTEIN P130; PROTEIN P27; R 406; TALABOSTAT; TANESPIMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE G0 PHASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RELIABILITY; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGNOSIS; RNA, SMALL INTERFERING; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 78549270421     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.08.008     Document Type: Article

References (41)

1. Messmer B.T., Messmer D., Allen S.L., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
2. Damle R.N., Temburni S., Calissano C., et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007, 110:3352-3359.
3. Moreno C., Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008, 22:211-219.
4. Rassenti L.Z., Jain S., Keating M.J., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112:1923-1930.
5. Chen L., Apgar J., Huynh L., et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005, 105:2036-2041.
6. Gobessi S., Laurenti L., Longo P.G., Sica S., Leone G., Efremov D.G. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007, 109:2032-2039.
7. Underwood R., Chiravuri M., Lee H., et al. Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 1999, 274:34053-34058.
8. Chiravuri M., Schmitz T., Yardley K., Underwood R., Dayal Y., Huber B.T. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol 1999, 163:3092-3099.
9. Danilov A.V., Klein A.K., Lee H.J., Baez D.V., Huber B.T. Differential control of G0 programme in chronic lymphocytic leukaemia: a novel prognostic factor. Br J Haematol 2005, 128:472-481.
10. Danilova O., Li B., Szardenings A.K., Huber B.T., Rosenblum J.S. Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg Med Chem Lett 2007, 17:507-510.
11. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
12. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
13. Krober A., Seiler T., Benner A., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
14. Wilda M., Bruch J., Harder L., et al. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia 2004, 18:584-588.
15. Mele D.A., Bista P., Baez D.V., Huber B.T. Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle 2009, 8:2425-2434.
16. Lin K., Sherrington P.D., Dennis M., Matrai Z., Cawley J.C., Pettitt A.R. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002, 100:1404-1409.
17. Kern W., Dicker F., Schnittger S., Haferlach C., Haferlach T. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 2009, 76:385-393.
18. Ho A., Dowdy S.F. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 2002, 12:47-52.
19. Obaya A.J., Kotenko I., Cole M.D., Sedivy J.M. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J Biol Chem 2002, 277:31263-31269.
20. Kelly K., Cochran B.H., Stiles C.D., Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983, 35(3 Pt 2):603-610.
21. Vrhovac R., Delmer A., Tang R., Marie J.P., Zittoun R., Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998, 91:4694-4700.
22. Kurosaki T. Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol 2002, 2:354-363.
23. Lankester A.C., Schijndel G.M., Pakker N.G., Van Oers R.H., van Lier R.A. Antigen receptor function in chronic lymphocytic leukemia B cells. Leuk Lymphoma 1996, 24:27-33.
24. Allsup D.J., Kamiguti A.S., Lin K., et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005, 65:7328-7337.
25. Deglesne P.A., Chevallier N., Letestu R., et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res 2006, 66:7158-7166.
26. Monroe J.G. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006, 6:283-294.
27. Buchner M., Fuchs S., Prinz G., et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009, 69:5424-5432.
28. Evan G.I., Wyllie A.H., Gilbert C.S., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128.
29. Johnson A.J., Wagner A.J., Cheney C.M., et al. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 2007, 139:837-844.
30. Lin K., Rockliffe N., Johnson G.G., Sherrington P.D., Pettitt A.R. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene 2008, 27:2445-2455.
31. Castro J.E., Prada C.E., Loria O., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005, 106:2506-2512.
32. Damle R.N., Ghiotto F., Valetto A., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99:4087-4093.
33. Hamblin T.J., Oscier D.G. Chronic lymphocytic leukaemia: the nature of the leukaemic cell. Blood Rev 1997, 11:119-128.
34. Yusuf I., Fruman D.A. Regulation of quiescence in lymphocytes. Trends Immunol 2003, 24:380-386.
35. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
36. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
37. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007, 25:799-804.
38. Tam C.S., Shanafelt T.D., Wierda W.G., et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M.D. Anderson and Mayo Clinic experience. Blood 2009, 114:957-964.
39. Bista P., Mele D.A., Baez D.V., Huber B.T. Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Mol Immunol 2008, 45:3618-3623.
40. Sun A., Bagella L., Tutton S., Romano G., Giordano A. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem 2007, 102:1400-1404.
41. Chen L., Huynh L., Apgar J., et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008, 111:2685-2692.